26
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Traditional medicine as a potential treatment for Flammer syndrome

      letter

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Flammer syndrome and TSS, a Kampo medicine Flammer syndrome is a primary vascular dysregulation that is associated with characteristic clinical symptoms and examination findings [1, 2]. Although most patients with Flammer syndrome do not develop unrelated or distinct disease states, normal-tension glaucoma (NTG) has been reported as an associated condition [1, 2]. Konieczka et al. hypothesized that Flammer syndrome is associated with multiple sclerosis and other diseases [1–3] and suggested that treatment for Flammer syndrome may be prophylactic against related diseases that result from vascular dysregulation [3]. Currently, standardized diagnostic criteria or treatment protocols for Flammer syndrome have not been established [1]. However, based on traditional Japanese (Kampo) medicine, the formula tokishakuyakusan (TSS) could potentially affect Flammer syndrome. Kampo medicine was introduced to Japan about 1500 years ago and was derived from traditional Chinese medicine. Since then, Kampo medicine has been evolving according to Japanese character, physical constitution, environment, and circumstances. In Japan, TSS (Danggui Shaoyao San in Chinese) is primarily administered to women with gynecological disorders who experience a cold sensation in their extremities [4, 5]. According to the theory of Kampo medicine, TSS remedies blood deficiencies and improves blood circulation, as well as alleviates abnormal fluid retention in the body. Previous studies have indicated that TSS improves iron deficiency anemia [6–8] and leukorrhagia [9]. Moreover, it had been reported that TSS may increase cerebral blood flow [10, 11], reduce oxidative stress in the central nervous system [12], inhibit platelet aggregation [13], regulate thrombosis in endothelial cells [14], and relax vascular smooth muscle [15]. Table 1 shows the comparative clinical symptoms and signs between Flammer syndrome and the indications for use of TSS. The major characteristics of Flammer syndrome, which are more common in women, including low body mass index, cold extremities, and low blood pressure, are similar to the indications for use of TSS. In addition, other features that are not identified are described in Table 1. Table 1 Comparative characteristics of clinical symptoms and signs in patients with Flammer syndrome and indications for the use of tokishakuyakusan Flammer syndrome Indications for TSS use Common features Common in women Common in women Low body mass index Low body mass index Cold extremities Cold extremities Low blood pressure Low blood pressure Dizziness Dizziness Reduced feeling of thirst With or without thirst Feeling cold Feeling cold Headaches Headaches Tinnitus Tinnitus Other features Migraines Anemia Long sleep onset time General fatigue Increased pain sensitivity Edema Increased drug sensitivity Numbness of extremities Good smell perception Soft stool Reversible skin blotches Menstrual irregularity Perfectionism Dysmenorrhea Vaginal discharge Flammer syndrome and NTG NTG is a major comorbid disease of Flammer syndrome [1, 2]. In patients with Flammer syndrome, there is an increased rigidity of retinal vessels and impaired autoregulation of the ocular blood flow. In patients with comorbid glaucoma and Flammer syndrome, additional signs are observed including disc hemorrhages, increased retinal venous pressure, and activation of retinal astrocytes [1, 2]. Although glaucoma is one of the leading causes of vision loss, reduction of intraocular pressure is the only proven approach to treatment. However, reducing the intraocular pressure alone does not prevent the progression of visual field loss in all patients, since impaired ocular circulation can also contribute to the progression of glaucoma [16, 17]. Potential of TSS for treatment of NTG and Flammer syndrome Recently, we reported that TSS increases ocular blood flow in healthy participants without decreasing blood pressure [18]. We are currently investigating whether TSS improves ocular blood flow in patients with NTG. Herein, we describe a representative case of a 42-year-old man with migraine and cold sensitivity who was diagnosed as having NTG in October 2013. His intraocular pressure was 16/16 mmHg without treatment. Figure 1 shows a photograph of the fundus at the patient’s first visit to our hospital, which indicates enlarged optic nerve cupping and retinal nerve fiber layer defects. Visual field defects were also detected in this patient (Fig. 2). We administered TSS extract granules (Tsumura and Co., Tokyo, Japan), at 7.5 g/d for 33 weeks, from February to September 2014. Following TSS treatment, the major symptoms of Flammer syndrome in the patient including sensitivity to cold and migraine frequency clearly improved. Figure 3 shows the changes in ocular blood flow measured using laser speckle flowgraphy of the optic nerve head. The mean blur rate, which is the relative ocular blood flow in arbitrary units, improved after 9 and 33 weeks, as compared to the pre-treatment measurement. The mean changes in visual field during treatment for TSS were +0.07 db/year in the right eye and −0.25 db/year in the left eye. The ocular pressure of the patient before TSS treatment, after 9 weeks, and after 33 weeks were 16, 14, and 14 mmHg in the right eye and 17, 14, and 14 mmHg in the left eye, respectively. Blood pressure and pulse rate at the same time intervals were 108/75/89, 103/69/81, and 106/72/80, respectively. Fig. 1 Fundus photograph of a representative case (right/left). Retinal layer defects were observed (yellow arrows) Fig. 2 Visual field examination (right/left). A Humphrey 24-2 visual field test of the patient’s right eye shows an inferior-nasal defect. In addition, the visual field of the left eye shows inferior and upper-nasal defects associated with NTG Fig. 3 a Laser speckle flowgraphy images of the patients’ ocular circulation. The mean blur rate (MBR) images of the entire optic nerve head (ONH) before administration and at 9 and 33 weeks of TSS treatment (both eyes) (i): Composite blood flow map of the ONH before the administration of TSS. The MBR values are 12.5 (right eye) and 14.3 (left eye) (ii): Composite blood flow map of the ONH at 9 weeks of TSS treatment. The MBR values are 14.0 (right eye) and 16.8 (left eye) (iii): Composite blood flow map of the ONH at 33 weeks of TSS treatment. The MBR values are 14.5 (right eye) and 17.1 (left eye). b Dynamic changes in ocular blood flow (OBF) in response to TSS treatment. The rates of changes in ocular blood flow improved after 9 and 33 weeks, as compared to the pre-treatment measurements in both eyes Discussion This case highlights that TSS can improve both the clinical symptoms of Flammer syndrome, as well as ocular blood flow, and prevent the progression of NTG. Visual field defects were not progressive during the entire TSS treatment duration. No change in the hemodynamics of the case due to the TSS treatment was found and was consistent with the result of our previous study [18]. We are currently conducting a study on a larger population to confirm these findings. Impaired regulation of ocular blood flow is considered to be one of the causes of NTG. It has been reported that plasma endothelin-1 (ET-1) levels of NTG patients are significantly higher than those of healthy participants [19]. TSS extract granules weighing 7.5 g produced by Tsumura and Co. (Tokyo, Japan) contained 4.0 g Paeoniae Radix, 4.0 g Atractylodis Lanceae Rhizoma, 4.0 g Alismatis Rhizoma, 4.0 g Poria Sclerotium, 3.0 g Cnidii Rhizome, and 3.0 g Angelicae Radix. A previous study has reported that Alismatis Rhizoma and Poria Sclerotium inhibit the synthesis and expression of ET-1 in the glomeruli of nephritic rats [20]. Moreover, some studies have shown that TSS decreases ET levels in the ovary of rats but do not affect plasma ET levels [21, 22]. These studies suggest that TSS may inhibit the production of ET-1 at peripheral tissues without affecting ET-1 levels in plasma. However, no studies have evaluated the effects of TSS on ET-1 levels of retinal tissue and optic nerve head. Further study is needed to investigate the mechanism of the effect of TSS on ocular blood flow. Recently, the concept of suboptimal health status (SHS) was advocated from the perspective of predictive, preventive, and personalized medicine [23, 24]. SHS is characterized by ambiguous health complaints and recognized as a subclinical, reversible stage of chronic disease. This perspective is highly associated with Flammer syndrome, which may contribute to the progression or development of chronic diseases. Limitation The findings described herein are based on a single case; additional data from a case series are required to validate the efficacy of TSS. We have not yet investigated whether TSS statistically improves the clinical symptoms and signs of Flammer syndrome. Other common features may exist between Flammer syndrome and patients for whom TSS is indicated. Moreover, there are no reports on the frequency of Flammer syndrome in Japanese NTG patients. Further research is needed to determine the relationship between Flammer syndrome and TSS. Conclusion Several common clinical features exist between subjects with Flammer syndrome and those for whom TSS is indicated. If TSS significantly increases the ocular blood flow in patients with NTG, TSS would be a potential treatment for patients with comorbid normal tension glaucoma and Flammer syndrome. Kampo medicine has been used for disease treatment, as well as for minor physical and mental health conditions. TSS may have a prophylactic effect in patients with Flammer syndrome who are at risk of developing related diseases.

          Related collections

          Most cited references20

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          The primary vascular dysregulation syndrome: implications for eye diseases

          Vascular dysregulation refers to the regulation of blood flow that is not adapted to the needs of the respective tissue. We distinguish primary vascular dysregulation (PVD, formerly called vasospastic syndrome) and secondary vascular dysregulation (SVD). Subjects with PVD tend to have cold extremities, low blood pressure, reduced feeling of thirst, altered drug sensitivity, increased pain sensitivity, prolonged sleep onset time, altered gene expression in the lymphocytes, signs of oxidative stress, slightly increased endothelin-1 plasma level, low body mass index and often diffuse and fluctuating visual field defects. Coldness, emotional or mechanical stress and starving can provoke symptoms. Virtually all organs, particularly the eye, can be involved. In subjects with PVD, retinal vessels are stiffer and more irregular, and both neurovascular coupling and autoregulation capacity are reduced while retinal venous pressure is often increased. Subjects with PVD have increased risk for normal-tension glaucoma, optic nerve compartment syndrome, central serous choroidopathy, Susac syndrome, retinal artery and vein occlusions and anterior ischaemic neuropathy without atherosclerosis. Further characteristics are their weaker blood–brain and blood-retinal barriers and the higher prevalence of optic disc haemorrhages and activated astrocytes. Subjects with PVD tend to suffer more often from tinnitus, muscle cramps, migraine with aura and silent myocardial ischaemic and are at greater risk for altitude sickness. While the main cause of vascular dysregulation is vascular endotheliopathy, dysfunction of the autonomic nervous system is also involved. In contrast, SVD occurs in the context of other diseases such as multiple sclerosis, retrobulbar neuritis, rheumatoid arthritis, fibromyalgia and giant cell arteritis. Taking into consideration the high prevalence of PVD in the population and potentially linked pathologies, in the current article, the authors provide recommendations on how to effectively promote the field in order to create innovative diagnostic tools to predict the pathology and develop more efficient treatment approaches tailored to the person.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Flammer syndrome

            The new term Flammer syndrome describes a phenotype characterized by the presence of primary vascular dysregulation together with a cluster of symptoms and signs that may occur in healthy people as well as people with disease. Typically, the blood vessels of the subjects with Flammer syndrome react differently to a number of stimuli, such as cold and physical or emotional stress. Nearly all organs, particularly the eye, can be involved. Although the syndrome has some advantages, such as protection against the development of atherosclerosis, Flammer syndrome also contributes to certain diseases, such as normal tension glaucoma. The syndrome occurs more often in women than in men, in slender people than in obese subjects, in people with indoor rather than outdoor jobs, and in academics than in blue collar workers. Affected subjects tend to have cold extremities, low blood pressure, prolonged sleep onset time, shifted circadian rhythm, reduced feeling of thirst, altered drug sensitivity, and increased general sensitivity, including pain sensitivity. The plasma level of endothelin-1 is slightly increased, and the gene expression in lymphocytes is changed. In the eye, the retinal vessels are stiffer and their spatial variability larger; the autoregulation of ocular blood flow is decreased. Glaucoma patients with Flammer syndrome have an increased frequency of the following: optic disc hemorrhages, activated retinal astrocytes, elevated retinal venous pressure, optic nerve compartmentalization, fluctuating diffuse visual field defects, and elevated oxidative stress. Further research should lead to a more concise definition, a precise diagnosis, and tools for recognizing people at risk. This may ultimately lead to more efficient and more personalized treatment.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Rate of progression of glaucoma correlates with retrobulbar circulation and intraocular pressure.

              To evaluate the correlation between progression rate of glaucomatous damage and retrobulbar blood flow in an institutional setting. Retrospective, observational case series. Twenty open-angle glaucoma patients with at least five visual field examinations and progressive damage in at least one eye were included in the study. Mean +/- standard deviation follow-up time was 4.3 +/- 1.6 years. As an indicator of progression rate of visual field damage, the angle to a horizontal line of the slope of the regression line of the visual field index mean defect over time was calculated for one randomly selected eye per patient. The association between this angle and intraocular pressure, as well as retrobulbar color Doppler imaging measurements obtained at the beginning of the observation period, was analyzed by a multiple linear regression analysis in a stepwise forward approach. With a faster rate in progression of glaucomatous damage, a lower baseline end diastolic blood flow velocity in the central retinal artery (partial r = -.63; P <.0037) and a higher baseline intraocular pressure (partial r =.59; P <.0078) were noted (multiple r =.69; P <.0043). Rate of progression was not related to the extent of preexisting visual field damage. Independent of the extent of glaucomatous damage and intraocular pressure, the progression rate of glaucomatous visual field damage statistically correlates with retrobulbar hemodynamic variables.
                Bookmark

                Author and article information

                Contributors
                81-22-717-7294 , y.shiga@oph.med.tohoku.ac.jp
                81-22-717-7507 , takayama@med.tohoku.ac.jp
                Journal
                EPMA J
                EPMA J
                The EPMA Journal
                Springer International Publishing (Cham )
                1878-5077
                1878-5085
                8 May 2017
                8 May 2017
                June 2017
                : 8
                : 2
                : 171-175
                Affiliations
                [1 ]ISNI 0000 0004 0641 778X, GRID grid.412757.2, Department of Kampo Medicine, , Tohoku University Hospital, ; 1-1 Seiryo-machi, Aoba ward, Sendai, 980-8574 Japan
                [2 ]ISNI 0000 0001 2248 6943, GRID grid.69566.3a, Department of Ophthalmology, , Tohoku University Graduate School of Medicine, ; 1-2 Seiryo-machi, Aoba ward, Sendai, 980-8575 Japan
                [3 ]ISNI 0000 0001 2248 6943, GRID grid.69566.3a, Department of Advanced Ophthalmic Medicine, , Tohoku University Graduate School of Medicine, ; 1-2 Seiryo-machi, Aoba ward, Sendai, 980-8575 Japan
                [4 ]ISNI 0000 0001 2248 6943, GRID grid.69566.3a, Department of Retinal Disease Control, , Tohoku University Graduate School of Medicine, ; 1-2 Seiryo-machi, Aoba ward, Sendai, 980-8575 Japan
                Author information
                http://orcid.org/0000-0002-6388-4566
                Article
                91
                10.1007/s13167-017-0091-9
                5486530
                28725293
                b9b4450c-9ee6-4fe1-a664-17b95636e288
                © The Author(s) 2017

                Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

                History
                : 23 February 2017
                : 30 March 2017
                Categories
                Letter to the Editor
                Custom metadata
                © European Association for Predictive, Preventive and Personalised Medicine (EPMA) 2017

                Molecular medicine
                Molecular medicine

                Comments

                Comment on this article